0.055
0.000
(0.00%)
May 23 - Close
CVE
data delayed by 15 mins -
Disclaimer
Currency in CAD
| Range | 0.05 - 0.05 |
| 52 week | 0.03 - 0.07 |
| Open | 0.05 |
| Vol / Avg. | 93,000.00/45,318.00 |
| Mkt cap | 21.57M |
| P/E | 8.54 |
| Div/yield | - |
| EPS | 0.01 |
| Shares | 392.26M |
| Beta | 1.40 |
| Inst. own | - |
Events
Apr 1, 2013
Q2 2013 MedMira Inc Earnings Release
|
|
Key stats and ratios
| Q1 (Jan '13) | 2012 | |
| Net profit margin | 201.23% | 347.43% |
| Operating margin | -103.98% | 812.09% |
| EBITD margin | - | -220.59% |
| Return on average assets | 248.04% | 151.14% |
| Return on average equity | - | - |
| Employees | 65 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 1, 155 Chain Lake Drive
HALIFAX, NS B3S 1B3
Canada
+1-902-4501588 (Phone)
+1-902-4501580 (Fax)
HALIFAX, NS B3S 1B3
Canada
+1-902-4501588 (Phone)
+1-902-4501580 (Fax)
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
MedMira Inc. is a biotechnology company. The Company is engaged in the development and commercialization of rapid diagnostics and technology platforms. The Company, through its subsidiaries, is engaged in the research, development and manufacturing of rapid diagnostics and technologies. The Company operates in North America, Latin America/Caribbean, Europe, Asia Pacific and Other. It invests in research. The Company�s testing solutions provide hospitals, labs, clinics and individuals with rapid diagnosis for diseases, such as human immunodeficiency virus (HIV) and hepatitis C. The Company�s tests are sold under the Reveal, Multiplo and Miriad brands. Its products consist of HIV, H. Pylori and Syphilis.
Officers and directors
| Hermes Chan | President, Chief Executive Officer, Director | |
| Daniel Frid | Chief Financial Officer | |
| Sing Chan | Chief Operating Officer | |
| Michael Sidler | Director | |
| Markus M. Meile | Independent Director | |
| Romano Robusto | Independent Director | |
| Shou Ching Tang M.D. | Independent Director |